BREPCO BIOPHARMA Announces €5.66 Million in Funding For Research Into The Treatment Of Ill Premature Babies
BrePco Biopharma announced that they, in conjunction with a consortium of University Research Centres lead by Cork University Maternity Hospital, have successfully secured €5.66 million in funding for ongoing research into the treatment of critically ill premature newborns suffering from hypotension.
This is a common problem amongst the most premature infants and is often associated with tragic outcomes, including brain injury and death. The collaboration, which brings together experts from 13 centres across Ireland, Europe and Canada, will develop a standard of care and uniquely tailored products for treating low blood pressure in such patients. The programme is being funded in part by the European Commission’s Healthcare FP7 Programme.*